Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

Results of part 1 of the ESSENCE phase 3 trial, published in The New England Journal of Medicine, demonstrated that a greater proportion of patients with MASH achieved resolution of steatohepatitis ...

BAGSVÆRD, Denmark & PLAINSBORO, N.J., Nov. 10, 2025 /PRNewswire/ -- Novo Nordisk today presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, The Liver ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

SAN DIEGO — Semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, appears to safely and effectively treat metabolic dysfunction–associated steatohepatitis (MASH) among patients with ...

Semaglutide met both primary endpoints in part 1 of ESSENCE. Topline results were announced from part 1 of a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with metabolic ...

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of researchers has now discovered it can also do wonders for people who have ...

The MarketWatch News Department was not involved in the creation of this content. -- 11 new abstracts including MASH data to be presented at the 76th Annual AASLD The Liver Meeting(R), 7-11 November - ...

Novo Nordisk (NVO) announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated ...

Recent sales of a little-known stock, Madrigal Pharmaceuticals (NASDAQ: MDGL), could bode well for Novo Nordisk A/S (NYSE: ...

Semaglutide is not approved for the treatment of adults with MASH. Safety and efficacy are not established, and there is no guarantee that semaglutide will become commercially available for this use ...